3/12
08:03 am
vstm
Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
Low
Report
Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
3/5
01:08 pm
vstm
Verastem (VSTM) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
Verastem (VSTM) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/5
12:18 pm
vstm
Verastem (VSTM) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Verastem (VSTM) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/5
04:11 am
vstm
Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ... [Yahoo! Finance]
Medium
Report
Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ... [Yahoo! Finance]
3/4
09:02 pm
vstm
Verastem Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Verastem Q4 Earnings Call Highlights [Yahoo! Finance]
3/4
07:23 pm
vstm
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
Medium
Report
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
3/4
06:37 pm
vstm
Verastem outlines 2026 milestones with CO-PACK franchise set to be self-sustaining in H2 [Seeking Alpha]
Medium
Report
Verastem outlines 2026 milestones with CO-PACK franchise set to be self-sustaining in H2 [Seeking Alpha]
3/4
06:37 pm
vstm
Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/4
04:01 pm
vstm
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
Medium
Report
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
2/26
09:35 am
vstm
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board [Yahoo! Finance]
Low
Report
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board [Yahoo! Finance]
2/19
10:01 am
vstm
Verastem (NASDAQ:VSTM) was given a new $18.00 price target on by analysts at Mizuho.
Low
Report
Verastem (NASDAQ:VSTM) was given a new $18.00 price target on by analysts at Mizuho.
2/18
07:30 am
vstm
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Medium
Report
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
2/4
08:42 am
vstm
Verastem (NASDAQ:VSTM) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $18.00 price target on the stock.
Medium
Report
Verastem (NASDAQ:VSTM) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $18.00 price target on the stock.
2/4
07:30 am
vstm
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
Medium
Report
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
1/12
04:01 pm
vstm
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/30
03:38 pm
vstm
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC [Seeking Alpha]
Neutral
Report
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC [Seeking Alpha]
12/30
07:17 am
vstm
Verastem (NASDAQ:VSTM) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Verastem (NASDAQ:VSTM) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/29
04:01 pm
vstm
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Medium
Report
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
12/15
04:45 pm
vstm
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth [Yahoo! Finance]
Medium
Report
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth [Yahoo! Finance]
12/15
04:01 pm
vstm
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
Medium
Report
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
12/15
09:43 am
vstm
Verastem, Inc. (NASDAQ:VSTM) is favoured by institutional owners who hold 60% of the company [Yahoo! Finance]
Medium
Report
Verastem, Inc. (NASDAQ:VSTM) is favoured by institutional owners who hold 60% of the company [Yahoo! Finance]